StemCyte renewed strategic partnership with the Neonatal Research Institute at Sharp Mary Birch Hospital for Women & Newborns

BALDWIN PARK, Calif., May 26, 2017 /PRNewswire/ -- California-based StemCyte, Inc., is proud to announce a renewed strategic partnership with the Neonatal Research Institute at Sharp Mary Birch Hospital for Women & Newborns. 

The hospital is the largest maternity hospital in California, with more than 9,000 babies born there each year. The strategic partnership designed to enhance resources for collection, processing and banking of this vital potentially life-saving resource of cord blood stem cells as well as their availability for new research.

"The practice of helping babies by providing stem cells at birth has been around for a long time; it makes sense for the sickest infants," said Anup Katheria, MD, director of the Neonatal Research Institute. "We're focused on producing evidence that shows the benefits. We think this could become the foundation for practice-changing birthing techniques, transforming outcomes for the most critical of newborns nationwide."

As a California-based public/private cord blood banking company and with a strong research focus, StemCyte stands ready to help efficiently and effectively to support the partnership with Sharp HealthCare to educate expecting parents of their options, to ensure the information is delivered accurately and consistently, and to collect the cells in cord blood and process and store them with the highest quality standards in the industry.

"We are excited to work with the Sharp Mary Birch Neonatal Research Institute, and we are looking forward to maximizing the capacity for cord-blood banking. Residents of California and people around the world will benefit from the research and increased availability of umbilical cord blood stem cell transplant units." said Jonas C. Wang, Ph.D., CEO/ Chairman of StemCyte Group.

About StemCyte
StemCyte's rich history started with a mission of being dedicated to helping the world's physicians save more lives by providing high quality, safe and effective stem cell transplantation and therapy to all patients in need. Located in the US, India and Taiwan, StemCyte has supplied over 2100 cord blood products for over 40 life-threatening diseases to over 300 leading worldwide transplant centers.  StemCyte is actively involved in the development of stem cell therapies. StemCyte was the first to donate umbilical cord blood units (UCB) to Dr. Jaing of Chung Gung Memorial Hospital for his clinical trial to use UCB to treat and cure Beta Thalassemia.  More excitingly is the work and accomplishments of Prof Wise Young, MD, PhD.  Prof. Young has completed Phase II clinical trials on patients with chronic spinal cord injury with UCB and the results are extremely encouraging. StemCyte is chosen by the US Department of Health and Human Services to help establishing a public National Cord Blood Inventory. Its headquarters are located in Baldwin Park, CA.  To learn more visit www.StemCyte.com.

For more information call 626.646.2500

SOURCE StemCyte